Patents by Inventor Mark A. Holoboski
Mark A. Holoboski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765065Abstract: Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or adsence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: GrantFiled: February 6, 2017Date of Patent: September 19, 2017Assignee: ALLERGAN, INC.Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Publication number: 20170144999Abstract: Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis-CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Patent number: 9591935Abstract: Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: GrantFiled: June 30, 2008Date of Patent: March 14, 2017Assignee: ALLERGEN, INC.Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Publication number: 20140235681Abstract: Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: ?-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, ?2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.Type: ApplicationFiled: December 6, 2013Publication date: August 21, 2014Applicant: ALLERGAN, INC.Inventors: SCOTT M. WHITCUP, ROBERT M. BURK, DAVID W. OLD, YARIV DONDE, WHA-BIN IM, MARK A. HOLOBOSKI
-
Publication number: 20130245283Abstract: A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.Type: ApplicationFiled: April 23, 2013Publication date: September 19, 2013Applicant: Allergan, Inc.Inventors: Wha-Bin Im, Robert M. Burk, Mark Holoboski
-
Patent number: 8487091Abstract: Disclosed herein are compounds represented by the formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: February 25, 2009Date of Patent: July 16, 2013Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner, Yariv Donde, David W. Old
-
Patent number: 8193373Abstract: Compound having the formula below are disclosed herein: formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: December 4, 2007Date of Patent: June 5, 2012Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner
-
Publication number: 20110152328Abstract: Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: ?-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, ?2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.Type: ApplicationFiled: April 13, 2009Publication date: June 23, 2011Inventors: Scott M. Whitcup, Robert M. Burk, David W. Old, Yariv Donde, Wha-Bin Im, Mark A. Holoboski
-
Patent number: 7964634Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: GrantFiled: April 21, 2009Date of Patent: June 21, 2011Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Patent number: 7960378Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: March 17, 2009Date of Patent: June 14, 2011Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner
-
Patent number: 7872045Abstract: A method is disclosed herein comprising administering a compound and a second drug to an eye of a mammal for the treatment of glaucoma or the reduction of intraocular pressure, said compound represented by the general formula I; wherein A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.Type: GrantFiled: May 16, 2005Date of Patent: January 18, 2011Assignee: Allergan, Inc.Inventors: Robert M. Burk, Mark Holoboski, Scott M. Whitcup, Wha-Bin Im
-
Publication number: 20100280250Abstract: A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Inventors: Wha-Bin Im, Robert M. Burk, Mark Holoboski
-
Publication number: 20100063303Abstract: Compound having the formula below are disclosed herein: formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: December 4, 2007Publication date: March 11, 2010Applicant: ALLERGAN, INC.Inventors: Mark Holoboski, Robert M. Burk, Mari F. Posner
-
Publication number: 20090275646Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: ApplicationFiled: April 21, 2009Publication date: November 5, 2009Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Patent number: 7612082Abstract: Disclosed herein are methods and compositions related to compound 1 or compound 2 or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP4 receptor, or are prostaglandin EP4 antagonists.Type: GrantFiled: October 28, 2004Date of Patent: November 3, 2009Assignee: Allergan, Inc.Inventors: Larry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward, Achim H.-P. Krauss, Robert M. Burk, Yariv Donde, Mark Holoboski, David W. Old, June Chen
-
Publication number: 20090239930Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicant: ALLERGAN, INC.Inventors: Mark HOLOBOSKI, Robert M. BURK, Mari POSNER
-
Publication number: 20090227573Abstract: Disclosed herein are compounds represented by the formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: February 25, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner, Yariv Donde, David W. Old
-
Patent number: 7514462Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.Type: GrantFiled: June 6, 2007Date of Patent: April 7, 2009Assignee: Allergan, Inc.Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
-
Publication number: 20080132543Abstract: A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of a carbohydrate; or said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.Type: ApplicationFiled: October 24, 2005Publication date: June 5, 2008Inventors: Wha Bin Im, Yariv Donde, Mark Holoboski, David W. Old, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Robert M. Burk, Todd Gac
-
Publication number: 20070232660Abstract: A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.Type: ApplicationFiled: March 19, 2007Publication date: October 4, 2007Inventors: Wha-Bin Im, Robert M. Burk, Mark Holoboski